Recently, Advera Health released a comparative safety report of the HER2+ Antagonists. In this drug review, we analyzed FDA Adverse Event Reporting System (FAERS) and clinical trial data to better understand how the drugs in this class stacked up.
As 2016 winds down, am I the only one who feels exhausted?
Between pharma-bro inspired drug pricing madness, a political season that felt like a Bravo reality TV show, and Leicester City robbing my beloved Tottenham Hotspur of their first shot at a Premiere League championship in a very long time, I think John Oliver summed up this year best in this video.
Last December, Stat News wrote a scathing report on the chronic under reporting of clinical trial results. We followed that up in July with our own blog post, highlighting specific under reporting rates we’ve found in just a handful of indications.
Every June, on the heels of the ASCO annual conference, comes the American Diabetes Association (ADA) annual conference, with a data deluge that is difficult for even the most diligent industry watchers to keep up with. At time of writing, it is only midday on Tuesday and there are already huge headlines from the conference.
Oftentimes it’s hard for me to see the forest through the trees. Being responsible for the commercial outcome of what we are working to accomplish at Advera Health with an incredibly talented, albeit small, team can be daunting at best. At worst it is completely insanely chaotic. Ensuring sales forecasts are accurate for board and investor meetings, directing the marketing strategy for product launches like this week’s announcement of our multiple sclerosis coverage, and working out the details of big partnerships like the one we will soon be announcing with a large, national group purchasing organization (GPO) requires a lot of attention to detail, acutely managed with a long to-do list.
Managed Care Organizations are reviewing drugs well before a product is approved. According to a survey conducted by Dymaxium (the company behind the AMCP eDossier System) and presented in a recent webinar, 2 out of 3 healthcare decision makers begin to evaluate a drug at least 6 months prior to approval. The survey also indicates that the primary source of information that payers are using for these pre-approval evaluations is clinicaltrials.gov (CT.gov), and that manufacturers are not always responsive to requests for information pre-approval.
It was a big week for us here at Advera Health. On Tuesday we released Evidex™, the next generation of our drug informatics platform that combines annotated data from curated clinical trial results together with structured real world evidence. We are extremely excited about Evidex, as it provides the first end-to-end solution that greatly increases the speed and efficiency of drug reviews by our clients.
This week marks the sixth anniversary of the date that Bob Kyle, Henry Duong, and I incorporated Advera Health Analytics. We started this journey with a mission to improve patient outcomes by making drug safety data more accessible and actionable. We spent the early years developing our technologies, building our data delivery platform, and subjecting our early methodologies to peer review. Two years ago we began to commercialize our enterprise data product and since then we’ve grown exponentially.